AN EVALUATION OF POINT AND INTERVAL ESTIMATES IN POPULATION PHARMACOKINETICS USING NONMEM ANALYSIS

被引:29
作者
WHITE, DB
WALAWANDER, CA
TUNG, Y
GRASELA, TH
机构
[1] SUNY BUFFALO,SCH PHARM,DEPT PHARM,BUFFALO,NY 14260
[2] SUNY BUFFALO,SCH MED,DEPT SOCIAL & PREVENT MED,BUFFALO,NY 14260
[3] SUNY BUFFALO,DEPT STAT,BUFFALO,NY 14214
[4] SUNY BUFFALO,SCH PHARM,CTR PHARMACOEPIDEMIOL RES,BUFFALO,NY 14260
[5] NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,DEPT BIOMATH,BUFFALO,NY 14263
来源
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS | 1991年 / 19卷 / 01期
关键词
POPULATION PHARMACOKINETICS; NONMEM; SIMULATIONS; BIAS; STANDARD ERROR; CONFIDENCE INTERVALS; MONOEXPONENTIAL MODEL; CLINICAL TRIALS;
D O I
10.1007/BF01062194
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In a simulation study of the estimation of population pharmacokinetic parameters, including fixed and random effects, the estimates and confidence intervals produced by NONMEM were evaluated. Data were simulated according to a monoexponential model with a wide range of design and statistical parameters, under both steady state (SS) and non-SS conditions. Within the range of values for population parameters commonly encountered in research and clinical settings, NONMEM produced parameter estimates for CL, V, sigma-CL, and sigma-epsilon which exhibit relatively small biases. As the range of variability increases, these biases became larger and more variable. An important exception was bias in the estimate for sigma-v which was large even when the underlying variability was small. NONMEM standard error estimates are appropriate as estimates of standard deviation when the underlying variability is small. Except in the case of CL, standard error estimates tend to deteriorate as underlying variability increases. An examination of confidence interval coverage indicates that caution should be exercised when the usual 95% confidence intervals are used for hypothesis testing. Finally, simulation-based corrections of point and interval estimates are possible but corrections must be performed on a case-by-case basis.
引用
收藏
页码:87 / 112
页数:26
相关论文
共 25 条
[1]   AN EVALUATION OF POPULATION PHARMACOKINETICS IN THERAPEUTIC TRIALS .3. PROSPECTIVE DATA-COLLECTION VERSUS RETROSPECTIVE DATA ASSEMBLY [J].
ANTAL, EJ ;
GRASELA, TH ;
SMITH, RB .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 46 (05) :552-559
[2]   THE NONMEM SYSTEM [J].
BEAL, S ;
SHEINER, L .
AMERICAN STATISTICIAN, 1980, 34 (02) :118-119
[3]  
BEAL SL, 1982, CRIT REV BIOMED ENG, V8, P195
[4]  
BEAL SL, 1989, NONMEM USERS GUIDE 6, P8
[5]   PHARMACOKINETICS AND CLINICAL EFFECTS OF ALPRAZOLAM FOLLOWING SINGLE AND MULTIPLE ORAL DOSES IN PATIENTS WITH PANIC DISORDER [J].
CIRAULO, DA ;
BARNHILL, JG ;
BOXENBAUM, HG ;
GREENBLATT, DJ ;
SMITH, RB .
JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 26 (04) :292-298
[6]   STEADY-STATE PHARMACOKINETICS OF PHENYTOIN FROM ROUTINELY COLLECTED PATIENT DATA [J].
GRASELA, TH ;
SHEINER, LB ;
RAMBECK, B ;
BOENIGK, HE ;
DUNLOP, A ;
MULLEN, PW ;
WADSWORTH, J ;
RICHENS, A ;
ISHIZAKI, T ;
CHIBA, K ;
MIURA, H ;
MINAGAWA, K ;
BLAIN, PG ;
MUCKLOW, JC ;
BACON, CT ;
RAWLINS, M .
CLINICAL PHARMACOKINETICS, 1983, 8 (04) :355-364
[7]   NEONATAL POPULATION PHARMACOKINETICS OF PHENOBARBITAL DERIVED FROM ROUTINE CLINICAL-DATA [J].
GRASELA, TH ;
DONN, SM .
DEVELOPMENTAL PHARMACOLOGY AND THERAPEUTICS, 1985, 8 (06) :374-383
[8]   POPULATION PHARMACOKINETICS OF PROCAINAMIDE FROM ROUTINE CLINICAL-DATA [J].
GRASELA, TH ;
SHEINER, LB .
CLINICAL PHARMACOKINETICS, 1984, 9 (06) :545-554
[9]  
GRASELA TH, 1987, CLIN PH ARM THER, V42, P443
[10]   ESTIMATION OF GENTAMICIN CLEARANCE AND VOLUME OF DISTRIBUTION IN NEONATES AND YOUNG-CHILDREN [J].
KELMAN, AW ;
THOMSON, AH ;
WHITING, B ;
BRYSON, SM ;
STEEDMAN, DA ;
MAWER, GE ;
SAMBADONGA, LA .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 18 (05) :685-692